Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
MGNX's Cash-to-Debt is ranked higher than
76% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. MGNX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MGNX' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.76
MGNX's Equity-to-Asset is ranked higher than
67% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MGNX: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
MGNX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.26  Med: 0.8 Max: 0.9
Current: 0.76
-0.26
0.9
Interest Coverage No Debt
MGNX's Interest Coverage is ranked higher than
69% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MGNX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 6.81
Beneish M-Score: -1.89
WACC vs ROIC
23.93%
318.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -21.29
MGNX's Operating Margin % is ranked higher than
65% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. MGNX: -21.29 )
Ranked among companies with meaningful Operating Margin % only.
MGNX' s Operating Margin % Range Over the Past 10 Years
Min: -80.16  Med: -14.04 Max: 12.86
Current: -21.29
-80.16
12.86
Net Margin % -19.64
MGNX's Net Margin % is ranked higher than
65% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. MGNX: -19.64 )
Ranked among companies with meaningful Net Margin % only.
MGNX' s Net Margin % Range Over the Past 10 Years
Min: -80.16  Med: -12.44 Max: 13.1
Current: -19.64
-80.16
13.1
ROE % -13.11
MGNX's ROE % is ranked higher than
70% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. MGNX: -13.11 )
Ranked among companies with meaningful ROE % only.
MGNX' s ROE % Range Over the Past 10 Years
Min: -38.27  Med: -9.27 Max: -0.74
Current: -13.11
-38.27
-0.74
ROA % -10.56
MGNX's ROA % is ranked higher than
71% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. MGNX: -10.56 )
Ranked among companies with meaningful ROA % only.
MGNX' s ROA % Range Over the Past 10 Years
Min: -25.57  Med: -5.73 Max: 14.36
Current: -10.56
-25.57
14.36
ROC (Joel Greenblatt) % -97.66
MGNX's ROC (Joel Greenblatt) % is ranked higher than
66% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. MGNX: -97.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MGNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -648.31  Med: -65.18 Max: 250.31
Current: -97.66
-648.31
250.31
3-Year Revenue Growth Rate 35.80
MGNX's 3-Year Revenue Growth Rate is ranked higher than
82% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. MGNX: 35.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MGNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -68.5  Med: -47.15 Max: 35.8
Current: 35.8
-68.5
35.8
3-Year EBITDA Growth Rate 32.30
MGNX's 3-Year EBITDA Growth Rate is ranked higher than
82% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. MGNX: 32.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MGNX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 32.3
Current: 32.3
0
32.3
3-Year EPS without NRI Growth Rate 27.20
MGNX's 3-Year EPS without NRI Growth Rate is ranked higher than
77% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. MGNX: 27.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MGNX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -124.15 Max: 27.2
Current: 27.2
0
27.2
GuruFocus has detected 3 Warning Signs with Macrogenics Inc MGNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MGNX's 30-Y Financials

Financials (Next Earnings Date: 2018-08-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

MGNX Guru Trades in Q2 2017

Jim Simons 227,023 sh (+73.40%)
Julian Robertson 239,667 sh (unchged)
Ronald Muhlenkamp 13,167 sh (unchged)
John Griffin Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 1,084,417 sh (-8.16%)
» More
Q3 2017

MGNX Guru Trades in Q3 2017

Paul Tudor Jones 20,029 sh (New)
Steven Cohen 1,181,317 sh (+8.94%)
Julian Robertson 239,667 sh (unchged)
Ronald Muhlenkamp 12,752 sh (-3.15%)
Jim Simons 193,623 sh (-14.71%)
» More
Q4 2017

MGNX Guru Trades in Q4 2017

Columbia Wanger 410,002 sh (New)
Jim Simons 300,523 sh (+55.21%)
Steven Cohen 1,084,417 sh (-8.20%)
Ronald Muhlenkamp 10,515 sh (-17.54%)
Paul Tudor Jones 14,466 sh (-27.77%)
Julian Robertson 127,967 sh (-46.61%)
» More
Q1 2018

MGNX Guru Trades in Q1 2018

Joel Greenblatt 10,409 sh (New)
Paul Tudor Jones 39,062 sh (+170.03%)
Jim Simons 399,323 sh (+32.88%)
Steven Cohen 1,084,417 sh (unchged)
Ronald Muhlenkamp Sold Out
Julian Robertson Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2018-03-31 New Buy$18.89 - $32.46 $ 22.95-6%10,409
Ronald Muhlenkamp 2018-03-31 Sold Out 0.06%$18.89 - $32.46 $ 22.95-6%0
Julian Robertson 2018-03-31 Sold Out 0.38%$18.89 - $32.46 $ 22.95-6%0
Julian Robertson 2017-12-31 Reduce -46.61%0.37%$16.19 - $20.3 $ 22.9523%127,967
Ronald Muhlenkamp 2017-12-31 Reduce -17.54%0.01%$16.19 - $20.3 $ 22.9523%10,515
Ronald Muhlenkamp 2017-09-30 Reduce -3.15%$15.31 - $18.94 $ 22.9533%12,752
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XMCE:ROVI, OCSE:BAVA, SHSE:603566, ROCO:4174, NAS:ZLAB, SHSE:603718, SZSE:002022, XKRX:003000, XKRX:078160, NAS:NTLA, NAS:BOLD, NAS:ACOR, NAS:ADAP, NAS:RVNC, SZSE:002872, SHSE:600200, OSTO:HMED, TSXV:CRON, SZSE:300149, SAU:2070 » details
Traded in other countries:M55.Germany,
Headquarter Location:USA
Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

Top Ranked Articles about Macrogenics Inc

New Research Coverage Highlights Materialise NV, MacroGenics, GasLog Partners LP, TCP Capital, NantHealth, and Net 1 UEPS Technologies — Consolidated Revenues, Company Growth, and Expectations for 2018
MacroGenics to Present at Jefferies Global Healthcare Conference
5 Health Care Stocks Gurus Are Buying Akebia Therapeutics, Macrogenics on the list
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus. Read more...
MacroGenics to Present at Deutsche Bank Health Care Conference
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial Results
MacroGenics Announces Date of First Quarter 2018 Financial Results Conference Call
Investor Expectations to Drive Momentum within Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp, China Mobile (Hong Kong), MacroGenics, Diodes, CONSOL Coal Resources LP, and Advantage Oil & Gas — Discovering Underlying Factors of Influence
5 Health Care Stocks Gurus Are Buying These stocks have positions in gurus' portfolios
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus. Read more...
MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MacroGenics Announces Pricing of Public Offering of Common Stock

Ratios

vs
industry
vs
history
PB Ratio 3.39
MGNX's PB Ratio is ranked higher than
56% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. MGNX: 3.39 )
Ranked among companies with meaningful PB Ratio only.
MGNX' s PB Ratio Range Over the Past 10 Years
Min: 1.73  Med: 3.43 Max: 12.83
Current: 3.39
1.73
12.83
PS Ratio 5.33
MGNX's PS Ratio is ranked higher than
62% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MGNX: 5.33 )
Ranked among companies with meaningful PS Ratio only.
MGNX' s PS Ratio Range Over the Past 10 Years
Min: 1.21  Med: 9.07 Max: 66.44
Current: 5.33
1.21
66.44
Price-to-Operating-Cash-Flow 48.00
MGNX's Price-to-Operating-Cash-Flow is ranked lower than
83% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. MGNX: 48.00 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MGNX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 42.89  Med: 63.47 Max: 349.38
Current: 48
42.89
349.38
EV-to-EBIT -20.83
MGNX's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. MGNX: -20.83 )
Ranked among companies with meaningful EV-to-EBIT only.
MGNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -77  Med: -10.3 Max: 2441.2
Current: -20.83
-77
2441.2
EV-to-EBITDA -25.69
MGNX's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. MGNX: -25.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
MGNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -96.8  Med: -11.95 Max: 573.9
Current: -25.69
-96.8
573.9
EV-to-Revenue 4.47
MGNX's EV-to-Revenue is ranked higher than
72% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. MGNX: 4.47 )
Ranked among companies with meaningful EV-to-Revenue only.
MGNX' s EV-to-Revenue Range Over the Past 10 Years
Min: 2  Med: 7.1 Max: 50
Current: 4.47
2
50
Current Ratio 5.43
MGNX's Current Ratio is ranked higher than
67% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. MGNX: 5.43 )
Ranked among companies with meaningful Current Ratio only.
MGNX' s Current Ratio Range Over the Past 10 Years
Min: 1.32  Med: 7.04 Max: 17.84
Current: 5.43
1.32
17.84
Quick Ratio 5.43
MGNX's Quick Ratio is ranked higher than
68% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. MGNX: 5.43 )
Ranked among companies with meaningful Quick Ratio only.
MGNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.32  Med: 7.04 Max: 17.84
Current: 5.43
1.32
17.84
Days Sales Outstanding 16.57
MGNX's Days Sales Outstanding is ranked higher than
77% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. MGNX: 16.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
MGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.43  Med: 12.6 Max: 31.57
Current: 16.57
4.43
31.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.60
MGNX's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. MGNX: -9.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -216.5  Med: -106.3 Max: -9.6
Current: -9.6
-216.5
-9.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.68
MGNX's Price-to-Net-Cash is ranked higher than
70% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. MGNX: 4.68 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MGNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.29  Med: 4.25 Max: 9.94
Current: 4.68
2.29
9.94
Price-to-Net-Current-Asset-Value 4.42
MGNX's Price-to-Net-Current-Asset-Value is ranked higher than
70% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. MGNX: 4.42 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MGNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.25  Med: 4.02 Max: 9.52
Current: 4.42
2.25
9.52
Price-to-Tangible-Book 3.44
MGNX's Price-to-Tangible-Book is ranked higher than
65% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. MGNX: 3.44 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MGNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.16  Med: 3.53 Max: 8.75
Current: 3.44
2.16
8.75
Price-to-Median-PS-Value 0.58
MGNX's Price-to-Median-PS-Value is ranked higher than
67% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. MGNX: 0.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MGNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 1 Max: 6.82
Current: 0.58
0.15
6.82
Earnings Yield (Greenblatt) % -4.83
MGNX's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. MGNX: -4.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MGNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -47.8  Med: -5.25 Max: 1.5
Current: -4.83
-47.8
1.5

More Statistics

Revenue (TTM) (Mil) $160.38
EPS (TTM) $ -0.80
Beta3.50
Volatility29.32%
52-Week Range $14.36 - 32.74
Shares Outstanding (Mil)42.20

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 93 106 194
EBIT (Mil $) -134 -137 -155
EBITDA (Mil $) -126 -128 -145
EPS ($) -3.21 -3.17 -3.59
EPS without NRI ($) -3.21 -3.17 -3.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}